Sarepta Therapeutics (SRPT): next trial readout expected around 2026-10-31
$SRPT · Sarepta Therapeutics, Inc.Trials that could report in the next 12 months: 9BiopharmaCTG
Catalyst timeline
Dates are estimated from each trial's registered completion date — none are FDA decision dates. Counts trials that fit our shared poll budget, not everything SRPT is running — see methodology.
- 2026-10-31in 10wA Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
- 2026-12-31in 19wStudy of SRP-1003 in Participants With Type 1 Myotonic Dystrophy
- 2027-03-31in 32wStudy to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting
- 2027-05-31in 41wA Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
- 2027-11-30in 67wA First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
- 2027-12-31in 71wA Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort
- 2028-08-28in 106wA Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)
- 2028-12-31in 124wStudy of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1
- 2033-10-31in 376wA Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
Pipeline
| Program | Phase | Status | Primary completion | Trial |
|---|---|---|---|---|
| A Long-term Follow-up Study of Participants Who Received Delandistroge… | Phase 3 | Enrolling By Invitation | 2033-10-31 | NCT05967351 |
| Study of SRP-1001 in Adult and Adolescent Participants With Facioscapu… | Phase 1 | Recruitingstill enrolling patients | 2028-12-31 | NCT06131983 |
| A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability… | Phase 1 | Active Not Recruitingenrolled, still running | 2028-08-28 | NCT05876780 |
| A Gene Transfer Therapy Study to Evaluate the Safety of and Expression… | Phase 1 | Recruitingstill enrolling patients | 2027-12-31 | NCT04626674 |
| A First-in-human Study of the Effects of SRP-1005 in Participants With… | Phase 1 | Recruitingstill enrolling patients | 2027-11-30 | NCT07536061 |
| A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of D… | Phase 3 | Active Not Recruitingenrolled, still running | 2027-05-31 | NCT05881408 |
| Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Particip… | Phase 4 | Not Yet Recruitingnot open yet | 2027-03-31 | NCT07542314 |
| Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy | Phase 1 | Recruitingstill enrolling patients | 2026-12-31 | NCT06138743 |
+ 1 more tracked trial
| Program | Phase | Status | Primary completion | Trial |
|---|---|---|---|---|
| A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in … | Phase 3 | Active Not Recruitingenrolled, still running | 2026-10-31 | NCT03992430 |
Status-change history
Every ClinicalTrials.gov change recorded for SRPT's trials — a running history no other tracker shows.
No status changes detected yet for this ticker.
Frequently asked
When is SRPT's next PDUFA date?
No disclosed PDUFA date is currently tracked for this ticker.
What phase is SRPT's lead program in?
Phase 3 — active not recruiting.
Where does this data come from?
ClinicalTrials.gov v2 API (trial status + diffs) and company 8-K/press-release disclosures (PDUFA dates). Every number links to its source.